ラベタロール

ラベタロール · 2-ヒドロキシ-5-[1-ヒドロキシ-2-[(1-メチル-3-フェニルプロピル)アミノ]エチル]ベンズアミド · 5-[1-ヒドロキシ-2-[(1-メチル-3-フェニルプロピル)アミノ]エチル]サリチルアミド · 5-[1-ヒドロキシ-2-(4-フェニルブタン-2-イルアミノ)エチル]-2-ヒドロキシベンズアミド · 2-ヒドロキシ-5-{1-ヒドロキシ-2-[(4-フェニルブタン-2-イル)アミノ]エチル}ベンズアミド · LABETOLOL · Laβlol · ah5158

https://huagongshe.com/ja/chemical/3869

識別子と物理属性

CAS No.	36894-69-6
分子式	C19H24N2O3
平均分子量	328.4 g/mol
単同位体質量	328.17869263 g/mol
SMILES	CC(CCc1ccccc1)NCC(O)c1ccc(O)c(C(N)=O)c1
InChIKey	SGUAFYQXFOLMHL-UHFFFAOYSA-N
PubChem CID	3869
ChEMBL	CHEMBL429
ChEBI	CHEBI:6343
EC No.	253-258-3
DTXSID	DTXSID2023191
現地名	ラベタロール

化学・物理的性質

XLogP	3.1
極性表面積	95.6
水素結合供与体数	4
水素結合受容体数	4
回転可能結合数	8
重原子数	24
形式電荷	0
複雑度	385
医薬品	Pharmaceuticals -> Used in Switzerland
LogP（分配係数）	2.71.89
溶解度	5.78e-03 g/LDMSO : 125 mg/mL (380.62 mMNeed ultrasonic)
Human Drugs	Breast FeedingLactationMilk, HumanAntihypertensive AgentsAdrenergic Beta-AntagonistsAntiarrhythmicsPharmaceuticals
融点	195 - 196 °C188 °C
Physical Description	Solid
Stability/Shelf Life	Labetalol hydrochloride tablets should be stored in well closed containers at 2-30 °Ctablets in unit dose packages should be protected from excessive moisture. Labetalol hydrochloride injection should be stored at 2-30 °C and protected from light and freezing. Labetalol hydrochloride tablets and injection have an expiration date of 3 and 2 years, respectively, after the date of manufacture. /Labetalol hydrochloride/Labetalol hydrochloride is most stable in solutions having a pH of 2- 4. The drug is physically and chemically compatible with the following iv solutions: 5% dextrose0.9% sodium chloride2.5% dextrose and 0.45% sodium chloride5% dextrose and 0.2, 0.33, or 0.9% sodium chloride5% dextrose and lactated Ringer's or Ringer'slactated Ringer'sor Ringer's. Following dilution of labetalol hydrochloride injection with one of these iv solutions, solutions containing 1.25-3.75 mg/ml are stable for at least 24 hrs when refrigerated or stored at room temperature. In one study, these solutions were stable for at least 72 hrs at 4 or 25 °C. Appreciable changes in pH or osmolarity of these iv solutions did not occur following admixture of labetalol hydrochloride injection. The drug is physically and/or chemically incompatible with 5% sodium bicarbonate injectionlabetalol hydrochloride solutions containing 1.25-3.75 mg/ml in 5% sodium bicarbonate have a pH of 7.6-8 and form a white precipitate, probably the free base, within 6 hrs after admixture. /Labetalol hydrochloride/
Dissociation Constants	7.49.3pKa = 9.3
Collision Cross Section	175.2 Å² [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: TOXCASTSource Identifier: DTXSID0044654]176.41 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]178.1 Å² [M+H]+ [CCS Type: TWMethod: Major Mix IMS/Tof Calibration Kit (Waters)]
Other Experimental Properties	White crystalline solid from ethanol-ethyl acetatemp: 187-189 °Csol in water, ethanolinsol in ether, chloroform. /Labetalol hydrochloride/
沸点	552.7±50.0 °C(Predicted)
密度	1.200±0.06 g/cm3(Predicted)
貯蔵条件	Store at -20°C
pKa（酸解離定数）	pKa 7.41 ± 0.019.36± 0.01(H2O,t =25,I=0.15(KCl)，Ar)(Approximate)
外観・状態	Solid
色	White to Pale Orange
安定性	Hygroscopic
CAS データベース	36894-69-6(CAS DataBase Reference)
NISTの化学物質情報	Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-(36894-69-6)

安全性と法規制

GHS 分類	WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P203, P261, P264, P264+P265, P271, P273, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
規制情報	REACH registered substance: Labetalol (EC: 253-258-3)
その他の安全情報	IMAP assessments - Benzamide, 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]-: Environment tier I assessment
FDA 要件	Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended21 U.S.C. 321-392).The Approved Drug Products with Therapeutic Equivalence Evaluations List identifies currently marketed prescription drug products, incl labetalol hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. /Labetalol hydrochloride/
Special Reports	Prichard BNBeta-blocking Agents with Vasodilating Action. J Cardiovasc Pharmacol 19 (Suppl 1): S1-4 (1992). Beta-blocking agents with vasodilating action are discussed. Drugs have been developed that in addition to blocking the beta-receptor have an important peripheral vasodilator activity. Labetalol was the first drug of this group to be developed.Donnelly R, Macphee GJClinical Pharmacokinetics and Kinetic-dynamic Relationships of Dilevalol and Labetalol. Clin Pharmacokinet 21 (2): 95-109 (1991). A review comparing the availability, metabolism, pharmacokinetics, efficacy and side effects of th vasodilatory beta-blockers labetalol and its stereoisomer, dilevalol, is presented. The effects of patient age and smoking habits on the response to hypertension therapy with these 2 drugs are included.Jackson CD, Fishbein LA Toxicological Review of Beta-adrenergic Blockers. Fundam Appl Toxicol 6 (3): 395-422 (1986). Eighteen beta-adrenergic blockers have been reviewed and the available literature pertaining to their potential carcinogenicity, mutagenicity, and teratogenicity has been summarized and compared.

用途

説明

Labetalol is an α-adrenergic and α-1 blocking agent which caused contact dermatitis and a contact anaphylactoid reaction during patch testing in a nurse.

使用

Labetalol is used to treat essential hypertension.

一般的な説明

Labetalol is a phenylethanolamine derivative, is representative of a classof drugs that act as competitive blockers at α1-, β1-, andβ2-receptors. It is a more potent β-blocker than α-blocker.Because it has two asymmetric carbon atoms (1 and 1' ), it existsas a mixture of four isomers. It is this mixture that is usedclinically in treating hypertension. The different isomers,however, possess different α- and β-blocking activities. The -blocking activity resides solely in the (1R,1 'R) isomer,whereas the 1-blocking activity is seen in the (1S,1 R) and(1S,1'S) isomers, with the (1S,1'R) isomer possessing thegreater therapeutic activity.